ASSOCIATION OF JAK2 F617 ALLELE BURDEN WITH HEMATOLOGICAL PARAMETERS IN MPD PATIENTS

Objective: A point mutation in the JAK2 gene, resulting in the substitution of valine for phenylalanine (JAK2 V617F), has been associated with myeloproliferative disorders such as polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis, myelodysplastic syndromes, chronic myelomonocytic leukemia, systemic mastocytosis, chronic neutrophilic leukemia, and eosinophilic disorders. Material and Methods: The relation of JAK2 V617F mutation has been studied in myeloproliferative disorder patients by qPCR. The F617 allele was calculated using a standard calibration curve, including less and more than 50% mutational load groups. Results: A significant relation was found among wild type (wt), less and more than 50% groups, Regarding erythrocyte, hematocrit, platelet, and leukocyte levels. A statistically significant relation was found between wt and more than 50% of groups regarding hemoglobin levels. The mutational load increase has been shown to induce erythrocyte, hematocrit, and leukocyte levels, except platelet levels. Conclusion: In patients with myeloproliferative disorders, qPCR screening of JAK2 gene mutation is indicated.